3,235 drug assets, with the trial evidence graded and the reasoning shown

Each graded trial is scored on design, size, endpoint and blinding against a published rubric. Pipelines, readouts and financials come from ClinicalTrials.gov, SEC filings and company releases.

drug assets
3,235
companies
1,457
registry studies
87,277
graded trials
3,474

Next Phase 3 readouts

Full calendar →
  1. Nov 2026upadacitinibAtopic Dermatitis · AbbVie
  2. Nov 2026AbataceptRheumatoid Arthritis · Bristol-Myers Squibb
  3. Nov 2026retatrutideObesity · Eli Lilly
  4. Nov 2026metforminSteinert's Disease, Myotonic Dystrophy 1, Metformin
  5. Nov 2026ObicetrapibAtherosclerotic Cardiovascular Disease · A. Menarini
  6. Nov 2026TadalafilFontan Palliation · Eli Lilly

Estimated primary-completion dates from ClinicalTrials.gov. They move.

What a company page shows

Abivax's share price, with key events markedOpen Abivax →

Share price · ABVX

$83.83

Jan 2025 to 18 Nov 2026 · close as of 2026-11-18 · 24h delayed · vol 1.2M (1.3x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

  1. source ↗
  2. source ↗
  3. source ↗
  4. source ↗
  5. source ↗

What an asset page shows

Obefazimod, the drug behind marker 1Open obefazimod →
Reliablesignal

Evidence outlook · lead readout

ABTECT - Maintenance (NCT05535946) · Ulcerative Colitis

The completed lead evidence has the design features that historically survive confirmatory trials: randomized, controlled, and adequately powered against a prespecified clinically accepted endpoint.

ABTECT - Maintenance (NCT05535946): This trial randomized responder patients to obefazimod 25 mg, 50 mg, or placebo under triple-blind conditions, with a large sample size (over 1,100 participants enrolled across the program), and its primary endpoint was clinical remission, a hard, disease-defining measure of ulcerative colitis activity. The comparison clearly favored obefazimod over placebo with a large effect size and high statistical significance, meeting all the elements needed for strong evidence: real randomization, blinding, an adequately sized placebo control, a hard clinical endpoint, and a statistically significant favorable result.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Also in development:Crohn's Disease · Phase 2

  • Trial designThe signal grades the trial's design, size, endpoint and blinding.
  • The reasoning is shownEvery graded trial carries its rationale.
  • How the outlook works →

Tools

Browse by therapeutic area

Educational research only, not investment advice. Evidence quality is graded; securities never are.